Literature DB >> 1153607

[Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)].

R Oliver-Marti n, E Buschsenschultz, P Pichot, J Boissier.   

Abstract

24 depressed impatients received a standardized treatment by imipramine, 6 among them receiving also levomepromazine. Plasma concentration of imipramine and DMI were controlled weekly during the study, and standardized assessment of clinical state were made by a psychiatrist who was unware of biochemical findings. Interaction between the antidepressant and neuroleptic metabolism is shown by a significant increase of DMI levels, though the clinical effect of the drug association could not be asserted. The therapeutic effect seems mainly dependant of etiology of depression. Endogeneous depressions improve more than other types. Among endogenous depressions a significant correlation was found between the degree of clinical improvement after three weeks and DMI level, sum of imipramine + DMI level, but not with concentration of imipramine alone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1153607     DOI: 10.1007/bf00421078

Source DB:  PubMed          Journal:  Psychopharmacologia


  14 in total

1.  [Methodology of therapeutic trials in psychopharmacology (author's transl)].

Authors:  P Pichot
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1975-12-22

Review 2.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Effect of simultaneous treatment with low doses of perphenazine on plasma and urine concentrations of nortriptyline and 10-hydroxynortriptyline.

Authors:  P Kragh-Sorensen; O Borgå; M Garle; L Bolvig Hansen; C E Hansen; E F Hvidberg; N E Larsen; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1977-07-19       Impact factor: 2.953

4.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

Review 5.  Plasma level monitoring of tricyclic antidepressant therapy.

Authors:  L F Gram
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

6.  Interaction between amitriptyline and phenothiazine in man: effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response.

Authors:  B Vandel; S Vandel; G Allers; P Bechtel; R Volmat
Journal:  Psychopharmacology (Berl)       Date:  1979-10       Impact factor: 4.530

7.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.

Authors:  B Vandel; S Vandel; J M Jounet; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Cerebral pharmacokinetics of imipramine in rats after single and multiple dosages.

Authors:  W Daniel; A Adamus; M Melzacka; J Szymura; J Vetulani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-11       Impact factor: 3.000

Review 9.  Pharmacokinetic optimisation of therapy with newer antidepressants.

Authors:  P J Goodnick
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

10.  The demethylation of imipramine and clomipramine as apparent from their plasma kinetics.

Authors:  A Nagy; R Johansson
Journal:  Psychopharmacology (Berl)       Date:  1977-10-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.